Subscribe200$/product give away!

Submit an Article to Pharmacy HQ     
Please include the author's name, title, and citations.     

FASLODEX- fulvestrant injection

  1. Patient Information
  2. Risk Of Bleeding:
  3. Embryo-fetal Toxicity:
  4. Lactation:

Patient Information 

Advise the patient to read the FDA-approved patient labeling (Patient Information).


Risk Of Bleeding: 

Because FASLODEX is administered intramuscularly, it should be used with caution in patients with bleeding disorders, decreased platelet count, or in patients receiving anticoagulants (for example, warfarin)[seeWarnings and Precautions (5.1)].

Embryo-fetal Toxicity: 

Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception during treatment with FASLODEX and for one year after the last dose. Advise females to inform their healthcare provider of a known or suspected pregnancy[seeWarnings and Precautions (5.4)andUse in Specific Populations (8.1),(8.3)].


Advise women not to breastfeed during treatment with FASLODEX and for one year after the last dose[seeUse in Specific Populations (8.2)].

Combination Therapy

When FASLODEX is used in combination with palbociclib, abemaciclib, or ribociclib, refer to the respective Full Prescribing Information for Patient Counseling Information.

Your use of this website constitutes your agreement to the terms and conditions linked below:
Terms and Conditions | Resources
2017 © Copyright PharmacyHQ.com. Questions?
Please contact: phq.contact@gmail.com